Connor Clark & Lunn Investment Management Ltd. Buys 114,466 Shares of Illumina, Inc. (NASDAQ:ILMN)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1,073.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 125,126 shares of the life sciences company's stock after purchasing an additional 114,466 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.08% of Illumina worth $16,318,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the second quarter valued at about $34,000. Versant Capital Management Inc raised its position in shares of Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company's stock valued at $34,000 after acquiring an additional 246 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Focused Wealth Management Inc acquired a new position in Illumina in the third quarter worth $63,000. Finally, Hollencrest Capital Management acquired a new position in Illumina in the third quarter worth $63,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

ILMN stock traded up $5.41 on Thursday, reaching $137.09. 1,591,713 shares of the company were exchanged, compared to its average volume of 2,031,796. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 12 month low of $93.51 and a 12 month high of $156.66. The stock's fifty day moving average price is $140.39 and its 200 day moving average price is $124.61. The firm has a market capitalization of $21.74 billion, a PE ratio of -13.76 and a beta of 1.13.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Leerink Partners increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. HSBC upgraded Illumina from a "hold" rating to a "buy" rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Royal Bank of Canada lifted their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. UBS Group upped their target price on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, StockNews.com started coverage on shares of Illumina in a research report on Thursday, August 29th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.